Regulatory Lilly wins new FDA approval for eczema drug Ebglyss PharmaphorumLilly's Ebglyss has claimed an FDA approval for less-frequent maintenance dosing that could give it an edge over market leader Dupixent.Immunology & InflammationRead full story pharminent June 10, 2026 (Last updated: June 10, 2026) Pharmaphorum Lilly’s Ebglyss has claimed an FDA approval for less-frequent maintenance dosing that could give it an edge over market leader Dupixent. Immunology & Inflammation Read full story Post navigation Previous: Disc’s FDA meeting sets ‘clear path’ for embattled rare blood disease drugNext: Aquipta recommended by NICE for acute migraine treatment Related Stories Regulatory Ultragenyx wins FDA approval for first treatment targeting root cause of GSDIa pharminent August 20, 2026 Regulatory Regeneron wins FDA approval to challenge Ipsen for rare bone disease market pharminent August 20, 2026 Regulatory FDA grants accelerated approval to Ultragenyx’s Genglycos gene therapy pharminent August 20, 2026
